Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Long-Term Investments: 2022-2025

Historic Long-Term Investments for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $11.5 million.

  • Corvus Pharmaceuticals' Long-Term Investments fell 24.08% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year decrease of 24.08%. This contributed to the annual value of $12.5 million for FY2024, which is 22.22% down from last year.
  • As of Q3 2025, Corvus Pharmaceuticals' Long-Term Investments stood at $11.5 million, which was down 2.24% from $11.8 million recorded in Q2 2025.
  • Corvus Pharmaceuticals' 5-year Long-Term Investments high stood at $33.4 million for Q1 2022, and its period low was $11.5 million during Q3 2025.
  • Over the past 3 years, Corvus Pharmaceuticals' median Long-Term Investments value was $15.4 million (recorded in 2024), while the average stood at $15.1 million.
  • Data for Corvus Pharmaceuticals' Long-Term Investments shows a maximum YoY tumbled of 40.30% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Corvus Pharmaceuticals' Long-Term Investments stood at $21.9 million in 2022, then decreased by 26.30% to $16.1 million in 2023, then declined by 22.22% to $12.5 million in 2024, then declined by 24.08% to $11.5 million in 2025.
  • Its Long-Term Investments was $11.5 million in Q3 2025, compared to $11.8 million in Q2 2025 and $12.1 million in Q1 2025.